Omalizumab and allergen immunotherapy for respiratory allergies

Filippo, Maria De; Votto, Martina; Caminiti, Lucia; Carella, F.; Castro, Giovanna De; Landi, Massimo; Olcese, Roberta; Panasiti, Ilenia; Vernich, Mario; Barberi, Salvatore; Ciprandi, Giorgio; Marseglia, Gian Luigi

doi:10.15586/aei.v50i6.495

Cited by 7 publications

(6 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[54][55][56] Omalizumab was also proposed as add-on treatment in patients with allergic rhinitis and asthma undergoing specific AIT. 57 The role of omalizumab as an add-on to OIT or as a monotherapy in children with FA was evaluated by several studies. 58 Regarding PA, Brandström those treated with normal dose (p < .01), as well as higher median ratios for Ara h 2 IgE-ab/IgE (17% vs. 11%).…”

Section: Omalizumabmentioning

confidence: 99%

“…Several studies demonstrated the safety and efficacy of omalizumab in allergic diseases 54–56 . Omalizumab was also proposed as add‐on treatment in patients with allergic rhinitis and asthma undergoing specific AIT 57 . The role of omalizumab as an add‐on to OIT or as a monotherapy in children with FA was evaluated by several studies 58 .…”

Section: Omalizumabmentioning

confidence: 99%

See 1 more Smart Citation

Current state and advances in desensitization for peanut allergy in pediatric age

Foti Randazzese,

Panasiti,

Caminiti

et al. 2024

Pediatric Allergy Immunology

Self Cite

View full text Add to dashboard Cite

Peanut allergy affects about 1%–3% of the pediatric population in the world, with an important increase in the last decades. Nowadays, international guidelines recommend the early introduction of peanuts in the infant diet, with poor information about the quantity and the frequency of the intake. Allergen immunotherapy may represent the only therapeutic strategy able to modify the natural history of peanut allergy. In particular, oral immunotherapy showed the most promising results in terms of efficacy, but with significant rates of adverse reactions, mostly gastrointestinal. In 2020, the Food and Drug Administration and the European Medicines Agency approved Palforzia®, an oral drug for patients aged 4–17 years. Several studies are ongoing to improve the tolerability of oral immunotherapy and standardize the desensitization protocols. Sublingual immunotherapy permits to offer much lower doses than oral immunotherapy, but fewer adverse events are shown. Subcutaneous immunotherapy is associated with the greatest systemic adverse effects. Epicutaneous immunotherapy, for which Viaskin® patch was approved, has the highest safety profile. Innovative studies are evaluating the use of biological drugs, such as omalizumab or dupilumab, and probiotics, such as Lactobacillus rhamnosus, in monotherapy or associated with oral immunotherapy. Therapy for peanut allergy is constantly evolving, and new perspectives are ongoing to develop.image

show abstract

Section: Omalizumabmentioning

confidence: 99%

Section: Omalizumabmentioning

confidence: 99%

Current state and advances in desensitization for peanut allergy in pediatric age

Foti Randazzese,

Panasiti,

Caminiti

et al. 2024

Pediatric Allergy Immunology

Self Cite

View full text Add to dashboard Cite

show abstract

“…IgE antibody production is the most typical immunological response indicative of a food allergy [ 223 , 224 ]. Since an adverse immunological reaction to egg proteins causes atopic dermatitis and eosinophilic esophagitis, it follows that egg allergy is an IgE antibody-mediated allergy [ 225 , 226 ]. Egg proteins’ ability to provoke an immune response is reflected in their stability in the face of heat and enzymatic digestion [ 206 , 207 , 208 , 209 , 210 , 211 , 212 , 213 , 214 , 215 , 216 , 217 , 218 , 219 , 220 , 221 , 222 , 223 , 224 , 225 , 226 , 227 ].…”

Section: Allergenicity From Egg Proteinsmentioning

confidence: 99%

“…Since an adverse immunological reaction to egg proteins causes atopic dermatitis and eosinophilic esophagitis, it follows that egg allergy is an IgE antibody-mediated allergy [ 225 , 226 ]. Egg proteins’ ability to provoke an immune response is reflected in their stability in the face of heat and enzymatic digestion [ 206 , 207 , 208 , 209 , 210 , 211 , 212 , 213 , 214 , 215 , 216 , 217 , 218 , 219 , 220 , 221 , 222 , 223 , 224 , 225 , 226 , 227 ]. While both egg components contain proteins that can trigger an allergic reaction, the allergenic potential of EW proteins is greater than that of EY proteins.…”

Section: Allergenicity From Egg Proteinsmentioning

confidence: 99%

The Impact of Processing and Extraction Methods on the Allergenicity of Targeted Protein Quantification as Well as Bioactive Peptides Derived from Egg

et al. 2023

View full text Add to dashboard Cite

This review article discusses advanced extraction methods to enhance the functionality of egg-derived peptides while reducing their allergenicity. While eggs are considered a nutrient-dense food, some proteins can cause allergic reactions in susceptible individuals. Therefore, various methods have been developed to reduce the allergenicity of egg-derived proteins, such as enzymatic hydrolysis, heat treatment, and glycosylation. In addition to reducing allergenicity, advanced extraction methods can enhance the functionality of egg-derived peptides. Techniques such as membrane separation, chromatography, and electrodialysis can isolate and purify specific egg-derived peptides with desired functional properties, improving their bioactivity. Further, enzymatic hydrolysis can also break down polypeptide sequences and produce bioactive peptides with various health benefits. While liquid chromatography is the most commonly used method to obtain individual proteins for developing novel food products, several challenges are associated with optimizing extraction conditions to maximize functionality and allergenicity reduction. The article also highlights the challenges and future perspectives, including optimizing extraction conditions to maximize functionality and allergenicity reduction. The review concludes by highlighting the potential for future research in this area to improve the safety and efficacy of egg-derived peptides more broadly.

show abstract

“…Thus, when AIT is contraindicated, omalizumab may allow patients to be treated safely with AIT. On the other hand, allergic reactions occurred in some other patients in whom this combined approach was used [16].…”

Section: Anti-ige As An Add-on To Ait In Respiratory Allergymentioning

confidence: 99%

Biologic drugs and allergen immunotherapy: potential allies

Carlucci,

Spataro,

Daddato

et al. 2023

Explor Asthma Allergy

View full text Add to dashboard Cite

Allergen-specific immunotherapy (AIT) is a proven efficacy treatment for allergic rhinitis (AR), asthma, and Hymenoptera venom allergy, but its use in food allergy (FA) is still under investigation. Because some efficacy and safety concerns still remain, biologic drugs, including omalizumab and dupilumab, have been studied as an adjunctive therapy to AIT for these conditions. In this article, the evidence supporting the use of monoclonal antibodies (mAbs) as an add-on therapy to AIT for FA, AR, asthma, and Hymenoptera venom allergy has been reviewed. The review will delve into the mechanisms of action of different mAbs, their efficacy, and how they can be integrated into personalized medicine approaches to treat allergic diseases. Furthermore, future research areas will be considered. Evidence suggests that omalizumab in combination with AIT may be a beneficial option for respiratory allergies or food desensitisation, especially during the escalation or build-up phase, when adverse events are more frequent. Currently, there is a small number of well-structured clinical trials in Hymenoptera venom allergy, and the available data consist mainly of single-case reports that provide information of limited value. Dupilumab has been studied as adjunctive therapy in patients with respiratory and FAs. Clinical trials are ongoing to evaluate the efficacy of dupilumab as monotherapy or as an adjunct to oral immunotherapy (OIT) in peanut allergy. Other studies are investigating the use of dupilumab in patients with multiple FAs and as an adjunct to milk OIT. Overall, mAbs have the potential to improve outcomes in various allergic conditions when used as an add-on to AIT, especially during the build-up phase. Further research is needed to fully understand their optimal dosing and duration of treatment, as well as to identify which patients may benefit the most from these therapies.

show abstract

Omalizumab and allergen immunotherapy for respiratory allergies

Cited by 7 publications

References 29 publications

Current state and advances in desensitization for peanut allergy in pediatric age

Current state and advances in desensitization for peanut allergy in pediatric age

The Impact of Processing and Extraction Methods on the Allergenicity of Targeted Protein Quantification as Well as Bioactive Peptides Derived from Egg

Biologic drugs and allergen immunotherapy: potential allies

Contact Info

Product

Resources

About